The Technical Analyst
Viridian Therapeutics, [VRDN]
Exchange: Nasdaq Capital Market Sector: Healthcare Industry: Biotechnology
Viridian Therapeutics, Price, Forecast, Insider, Ratings, Fundamentals & Signals
0.48% $24.99
America/New_York / 6 jun 2023 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 1 077.88 mill |
| EPS: | 0 |
| P/E: | 0 |
| Earnings Date: | Aug 14, 2023 |
| SharesOutstanding: | 43.13 mill |
| Avg Daily Volume: | 0.621 mill |
| RATING 2023-06-06 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Buy | |
| Return On Equity: | Sell | |
| Return On Asset: | Sell | |
| DE: | Neutral | |
| P/E: | Strong Sell | |
| Price To Book: | Strong Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 4/21 | 1/22 | 2/22 | 3/22 | 4/22 | 1/23 | |
| Revenue | ||||||
| Gr.Profit | n/a | |||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE 0 | sector: PE 0 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.78x |
| Company: PE 0 | industry: PE 6.71 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$29.84 (19.40%) $4.85 |
| Date: 2023-06-07 |
| Expected Trading Range (DAY) |
|---|
|
$ 23.62 - 26.36 ( +/- 5.47%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2023-06-02 | Meisner Lara | Buy | 1 875 | Common Stock |
| 2023-06-02 | Meisner Lara | Sell | 1 875 | Common Stock |
| 2023-06-05 | Meisner Lara | Buy | 499 | Common Stock |
| 2023-06-05 | Meisner Lara | Sell | 499 | Common Stock |
| 2023-06-06 | Meisner Lara | Buy | 5 126 | Common Stock |
| INSIDER POWER |
|---|
| 62.41 |
| Last 94 transactions |
| Buy: 6 752 573 | Sell: 906 708 |
Forecast:
16:00 - $24.99
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $24.99
Forecast 2: 16:00 - $24.99
Forecast 3: 16:00 - $24.99
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $24.99 (0.48% ) |
| Volume | 0.555 mill |
| Avg. Vol. | 0.621 mill |
| % of Avg. Vol | 89.41 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For VRDN
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % |
|---|
VRDN
Viridian Therapeutics, Inc., a biotechnology company, develops treatments for patients suffering from serious diseases. It develops VRDN-001, a humanized monoclonal anti-IGF-1R antibody that is in Phase 1/2 clinical trial for the treatment of thyroid eye disease (TED); VRDN-002, an IGF-1R antibody, which is in Phase 1 clinical trial; and VRDN-003, a therapeutic antibody targeting IGF-1R for the treatment of TED. The company was formerly known as Miragen Therapeutics, Inc. and changed its name to Viridian Therapeutics, Inc. in January 2021. Viridian Therapeutics, Inc. was founded in 2006 and is headquartered in Waltham, Massachusetts.
Latest Press Releases
2023-06-05 16:05:00 - Press Release
Viridian Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Waltham, mass.--(business wire)--viridian therapeutics, inc. (nasdaq: vrdn) (the “company” or “viridian”), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that a majority of the independent directors serving on the compensation committee of the company's board of directors approved the grant of non-qualified stock options to purchase an aggregate of 315,000 shares of the company's common stock to.
2023-05-08 08:00:00 - Press Release
Viridian Therapeutics Announces Partnership With Drug Delivery Innovator Enable Injections
- partnership to support one of the company's preclinical programs outside of thyroid eye disease (ted) - waltham, mass., may 08, 2023 (globe newswire) -- viridian therapeutics, inc. (nasdaq: vrdn), a biotechnology company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced a new partnership with enable injections, a company developing and manufacturing the enfuse® innovative wearable drug delivery system for volumes of up to 25ml.
2023-04-20 13:41:00 - Press Release
Update – Viridian Therapeutics Announces Presentations At The 2023 Annual Meeting Of The Association For Research In Vision And Ophthalmology
- presentations to cover updated clinical and preclinical data on pipeline candidates in company's thyroid eye disease program -
2023-04-20 08:00:00 - Press Release
Viridian Therapeutics Announces Presentations At The 2023 Annual Meeting Of The Association For Research In Vision And Ophthalmology
- presentations to cover updated clinical and preclinical data on pipeline candidates in company's thyroid eye disease program -
2023-04-12 08:00:00 - Press Release
Viridian Therapeutics Appoints Tony Casciano As Chief Commercial Officer
Waltham, mass., april 12, 2023 (globe newswire) -- viridian therapeutics, inc. (nasdaq: vrdn), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced the appointment of tony casciano to the role of chief commercial officer (cco). the company also announced that chief operating officer (coo) carrie melvin is no longer with the organization.
Latest News
2023-05-13 18:02:01 - Seeking Alpha
Viridian Therapeutics, Inc. (VRDN) Q1 2023 Earnings Call Transcript
Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q1 2023 Results Conference Call May 9, 2023 4:30 PM ET Company Participants Louisa Stone - Manager, IR Scott Myers - President and CEO Kristian Humer - Chief Financial and Business Officer Dr. Thomas Ciulla - Chief Development Officer Todd James - SVP, Corporate Affairs and IR Conference Call Participants Derek Archila - Wells Fargo Gavin Clark-Gartner - Evercore ISI Thomas Smith - SVB Securities Laura Chico - Wedbush Securities Kalpit Patel - B. Riley Securities Jason Butler - JMP Securities Rami Katkhuda - LifeSci Operator Welcome to the Viridian Therapeutics First Quarter 2023 Conference Call.
2023-05-09 18:20:05 - Zacks Investment Research
Viridian Therapeutics, Inc. (VRDN) Reports Q1 Loss, Misses Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) came out with a quarterly loss of $1.61 per share versus the Zacks Consensus Estimate of a loss of $1. This compares to loss of $0.98 per share a year ago.
2023-04-11 15:20:10 - Seeking Alpha
Viridian: A Second Buying Opportunity, But I Am Waiting For A Better Price
Viridian Therapeutics, Inc. has been a profitable investment for me. I am trying to get in again.
2023-03-08 14:46:30 - Seeking Alpha
Viridian Therapeutics, Inc. (VRDN) Q4 2022 Earnings Conference Call
Viridian Therapeutics, Inc. (NASDAQ:VRDN ) Q4 2022 Earnings Conference Call March 8, 2023 8:00 PM ET Company Participants Louisa Stone - Manager, Investor Relations Scott Myers - President and Chief Executive Officer Kristian Humer - Chief Financial Officer Deepa Rajagopalan - Chief Product and Strategy Officer Todd James - Senior Vice President, Corporate Affairs and Investor Relations Conference Call Participants Gavin Clark-Gartner - Evercore ISI Laura Chico - Wedbush Securities Jason Butler - JMP Securities Sam Slutsky - LifeSci Capital Kalpit Patel - B. Riley Securities Douglas Tsao - H.C.
2023-03-08 09:47:39 - Zacks Investment Research
Viridian Therapeutics, Inc. (VRDN) Reports Q4 Loss, Lags Revenue Estimates
Viridian Therapeutics, Inc. (VRDN) delivered earnings and revenue surprises of -56.94% and 85.25%, respectively, for the quarter ended December 2022. Do the numbers hold clues to what lies ahead for the stock?
2023-03-01 08:00:00 - GlobeNewsWire
Viridian Therapeutics to Webcast Fourth Quarter and Full Year 2022 Financial Results on March 8, 2023
WALTHAM, Mass., March 01, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced it will host a webcast and conference call on Wednesday, March 8, 2023 at 8:00 a.m. ET to discuss its fourth quarter and full year 2022 financial results.
2023-01-25 13:14:51 - Seeking Alpha
Why Viridian Therapeutics Is One Of My 2023 Top Picks
Viridian was one of my top picks in 2022 and it made the 2023 list again. VRDN-001 data continue to impress and Viridian looks well-positioned to disrupt the thyroid eye disease market later this decade.
2023-01-03 08:00:00 - GlobeNewsWire
Viridian Therapeutics to Webcast Presentation at the 41st Annual J.P. Morgan Healthcare Conference
WALTHAM, Mass., Jan. 03, 2023 (GLOBE NEWSWIRE) -- Viridian Therapeutics, Inc. (NASDAQ: VRDN), a biopharmaceutical company focused on discovering and developing potential best-in-class medicines for serious and rare diseases, today announced that its President and Chief Executive Officer, Jonathan Violin, Ph.D., will present an overview of the company along with its upcoming corporate priorities at the 41st Annual J.P. Morgan Healthcare Conference on Monday, January 9, 2023 at 2:15 p.m. PST / 5:15 p.m. EST in San Francisco, California.
2023-01-02 10:12:13 - Seeking Alpha
MDA Breakout Stocks Week 1 - January 2023: High-Frequency Gainers To Give You An Edge
Two new Breakout Stocks for Week 1 with better than 10% short-term upside potential and two Dow 30 Picks. Average cumulative returns for 2022 reached +142.69% YTD. The streak of weekly picks gaining over 10% in less than a week of trading days has reached 235 out of 293 trading weeks (80.4%) not counting multiple gainers.
2022-12-15 08:00:00 - Seeking Alpha
Viridian: Better Data Than A Blockbuster Competitor
Viridian Therapeutics, Inc.'s data in TED beats Tepezza's trial data. Tepezza is a blockbuster drug.